Superior efficacy of Iptacopan in PNH patients
Oral monotherapy with Iptacopan, a proximal complement inhibitor of factor B, has been compared with the standard of care with eculizumab or ravulizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH) and residual anemia. The superior effects of Iptacopan are elaborated by professor Régis Peffault de Latour, in this MEDtalk.
Get access to the article
If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.